<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="143846">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01228149</url>
  </required_header>
  <id_info>
    <org_study_id>35131; EUDRA CT 2010-019975-30</org_study_id>
    <nct_id>NCT01228149</nct_id>
  </id_info>
  <brief_title>COSOPT-S® Treatment Versus Acetazolamide Before Trabeculectomy</brief_title>
  <official_title>Investigation of the Efficacy and Safety of Preoperative IOP Reduction With Preservative-free COSOPT-S® (Dorzolamide/Timolol, MSD) Eye Drops Versus Oral Acetazolamide and Dexamethasone Eye Drops</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Katrin Lorenz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johannes Gutenberg University Mainz</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The most common cause of post-trabeculectomy filtration failure is postoperative scarring.
      Long-term preoperative treatment with local antiglaucoma agents containing preservatives has
      an increased risk of post-operative scarring of the filtration bleb. Therefore many surgeons
      prepare their patients for planned trabeculectomy by discontinuing local antiglaucoma drugs,
      controlling IOP with oral acetazolamide, and treating the eye with local steroids.

      Preservative-free COSOPT-S® eye drops b.i.d now provide a possibility to reduce IOP
      preoperatively with the aim of avoiding postoperative excessive scarring and the known
      adverse effects of oral acetazolamide while achieving comparable IOP reduction and long-term
      outcomes.

      This study will investigate comparability (non-inferiority) of medical benefits of two
      different IOP lowering pharmaceutical interventions prior to trabeculectomy comparing
      COSOPT-S® bid to oral acetazolamide plus dexamethasone.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean IOP reduction (ΔIOP) three months after trabeculectomy in comparison to the mean preoperative IOP</measure>
    <time_frame>12 weeks</time_frame>
    <description>measurement of eye pressure in mmHg</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>safety of both treatment arms</measure>
    <time_frame>12 weeks</time_frame>
    <description>Safety and tolerability of both treatment arms Number of necessary 5FU injections and suture lyses Required number of needlings and reoperations Change in IOP between Visit 1 and 2 Comparison between both groups of ocular hypotension rate and filtration bleb classification in both groups at every postoperative visit.
Change in quality of life for the two therapeutical regimens in both groups Patients' satisfaction with pharmacologic intervention for IOP lowering</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">65</enrollment>
  <condition>Glaucoma</condition>
  <arm_group>
    <arm_group_label>Acetazolamide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive oral acetazolamide starting 28 days preoperatively. 7 days preoperatively dexamethasone eyedrops without preservatives are applied additionally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cosopt S</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive Cosopt S eye drops starting 28 days preoperatively</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Trabeculectomy</intervention_name>
    <description>Filtrating glaucoma surgery, preoperative treatment will be assessed.</description>
    <arm_group_label>Acetazolamide</arm_group_label>
    <arm_group_label>Cosopt S</arm_group_label>
    <other_name>Filtrating glaucoma surgery</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients aged 18 years or older

          -  Caucasian

          -  A clinical diagnosis of open angle glaucoma, pseudoexfoliation or pigment dispersion
             glaucoma, or ocular hypertension in one or both eyes

          -  Planned trabeculectomy

          -  Previous treatment with antiglaucoma agents containing preservatives for at least one
             month

          -  Best corrected visual acuity of 20/800 or better in the study eye

        Exclusion Criteria:

          -  Secondary glaucoma except pseudoexfoliation glaucoma and pigmentary glaucoma

          -  Current ocular infection, i.e. conjunctivitis or keratitis

          -  Any abnormality preventing reliable applanation tonometry

          -  Intraocular surgery or laser treatment within the past three months

          -  History of surgery involving the conjunctiva

          -  History of cataract surgery with sclerocorneal approach

          -  Subject is allergic to sulfonamides

          -  Reactive airway disease, including bronchial asthma or a history of bronchial asthma,
             or severe chronic obstructive pulmonary disease

          -  Sinus bradycardia, second or third degree atrioventricular block, overt cardiac
             failure, cardiogenic shock

          -  Severe renal dysfunction (CrCl &lt; 30 ml/min) or hyperchloraemic acidosis

          -  Depressed blood levels of sodium and / or potassium

          -  Marked kidney and liver disease or dysfunction, gout, suprarenal gland failure,
             hypercalciuria or nephrocalcinosis

          -  History of hypersensitivity to the investigational medicinal products or to any drug
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Katrin Lorenz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johannes Gutenberg University Mainz</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Trial Site, Department of Ophthalmology, University Medical Center Johannes Gutenberg University Mainz</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <lastchanged_date>September 10, 2014</lastchanged_date>
  <firstreceived_date>August 20, 2010</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Johannes Gutenberg University Mainz</investigator_affiliation>
    <investigator_full_name>Katrin Lorenz</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>glaucoma</keyword>
  <keyword>trabeculectomy</keyword>
  <keyword>intraocular pressure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glaucoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Acetazolamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
